Prestige Consumer Healthcare (PBH) Projected to Post Quarterly Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is expected to post its Q3 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $1.16 per share and revenue of $286.9320 million for the quarter. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Investors are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. The business had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. Prestige Consumer Healthcare’s quarterly revenue was down 3.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.09 earnings per share. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $63.18 on Thursday. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55. The firm has a market cap of $3.04 billion, a price-to-earnings ratio of 15.68, a PEG ratio of 2.01 and a beta of 0.40. The company’s fifty day simple moving average is $62.32 and its 200 day simple moving average is $64.48. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $90.04.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PBH. Jefferies Financial Group cut their target price on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research report on Monday, October 27th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Oppenheimer lowered their price objective on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Canaccord Genuity Group reduced their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a report on Friday, November 7th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.33.

Insiders Place Their Bets

In other news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the transaction, the vice president directly owned 42,329 shares of the company’s stock, valued at $2,539,740. This represents a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Institutional investors have recently bought and sold shares of the company. Danske Bank A S purchased a new stake in Prestige Consumer Healthcare in the third quarter worth $37,000. Brown Brothers Harriman & Co. purchased a new stake in Prestige Consumer Healthcare in the 3rd quarter worth about $44,000. Geneos Wealth Management Inc. raised its stake in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in Prestige Consumer Healthcare by 142.8% during the third quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company’s stock valued at $69,000 after purchasing an additional 647 shares during the last quarter. Finally, State of Wyoming purchased a new stake in Prestige Consumer Healthcare during the second quarter valued at about $97,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).